• REC8 Stabilizes MAVS and STING in Antiviral Immunity

  2026-09-11

  The reference study identifies REC8, a protein traditionally associated with meiosis and chromosome cohesion, as a positive regulator of antiviral innate immunity. It shows that SUMOylated REC8 relocates to the cytoplasm, stabilizes MAVS and STING by limiting RNF5-driven K48-linked ubiquitination, and promotes TBK1 recruitment.

• Ruxolitinib–oHSV Immune Remodeling in Murine Sarcoma

  2026-09-11

  This study developed a 46-color spectral flow cytometry panel to characterize immune remodeling after combined Ruxolitinib and oncolytic herpes simplex virus treatment in murine malignant peripheral nerve sheath tumors. The combination was associated with greater CD4 T-cell functional diversity, activated germinal center B-cell populations, and broader lymphoid and myeloid changes, providing a more complete view of the tumor immune microenvironment.

• B. fragilis, Vagal Cholinergic Signaling, and Seizures

  2026-09-10

  The reference study identifies a colonic ChAT-positive cell–vagus–brain circuit through which Bacteroides fragilis suppresses seizures, linking microbiota ecology with acetylcholine neurotransmitter signaling. Its combination of mouse circuit experiments and a randomized pediatric trial provides a mechanistic framework for evaluating microbiota-directed approaches in refractory epilepsy.

• ATS-9R for Adipocyte Gene Silencing

  2026-09-10

  ATS-9R enables non-viral, Prohibitin-directed delivery of shRNA and sgRNA/Cas9 cargo to white adipose tissue, offering a practical route to study adipocyte biology and adipose inflammation. This guide translates formulation, dosing, assay-selection, and troubleshooting considerations into workflows for obesity, insulin resistance, and metabolic disease research.

• Light-Inducible RNA Release for Regulated Gene Therapy

  2026-09-09

  The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that regulates mammalian translation without requiring a separate effector domain. In vivo demonstrations across metabolic and retinal disease models show how light-responsive translational control could improve the timing, reversibility, and safety of gene therapies.

• Degarelix acetate Research Workflow

  2026-09-09

  Build more reproducible GnRH receptor antagonist assays by pairing concentration-controlled hormone studies with aggregation-aware sample handling. This workflow connects receptor binding, hormone secretion inhibition, and peptide formulation checks for prostate cancer research.

• MDM1, p53, and CRC Chemoradiotherapy Sensitivity

  2026-09-08

  The reference study identifies MDM1 as a mechanistic determinant of colorectal cancer response to chemoradiotherapy, linking MDM1 expression to YBX1-dependent TP53 regulation and apoptosis. Its integrated genetic, transcriptomic, cellular, and xenograft evidence supports MDM1 as a candidate predictive biomarker and highlights apoptosis modulation as a possible route to restore treatment sensitivity.

• pH-Responsive cRGD-PEG-siRNA for Glioblastoma

  2026-09-08

  The 2024 Bioconjugate Chemistry study developed a pH-responsive cRGD-PEG-siEGFR conjugate designed to improve glioblastoma targeting, serum stability, circulation time, and renal safety relative to an earlier cRGD-siRNA format. Its experiments linked αvβ3-selective uptake in U87MG cells with EGFR silencing, antitumor activity, and reduced renal accumulation, while also defining important questions for translation beyond the reported models.

• FPH1 (BRD-6125) Hepatocyte Assay Guide

  2026-09-07

  FPH1 (BRD-6125) helps pair hepatocyte expansion with functional readouts such as albumin, CYP3A4, AFP, nuclei count, and mitotic activity. This practical guide covers dosing, iPSC-derived hepatocyte workflows, troubleshooting, and a carefully bounded connection to light-controlled gene regulation.

• Ac-YVAD-CMK for Kupffer Cell Pyroptosis Assays

  2026-09-07

  Ac-YVAD-CMK helps separate caspase-1-dependent cytokine maturation from upstream membrane injury in Kupffer cell inflammation models. This workflow translates TMEM16F–Listeria findings into practical controls for measuring pyroptosis, IL-1β/IL-18 release, and liver-cell damage.

• NLRP10, Keratinocyte Survival, and Skin Barrier Function

  2026-09-05

  The reference study identifies NLRP10 as a functional regulator of epidermal homeostasis, extending its association with atopic dermatitis beyond genetics to keratinocyte survival, p63-dependent differentiation, and barrier integrity. Its human skin-equivalent model and mechanistic analysis position NLRP10 as a candidate pathway for studying how impaired cell survival and differentiation contribute to atopic dermatitis.

• Western Secondary Antibody Dilution Buffer Guide

  2026-09-04

  Western Secondary Antibody Dilution Buffer K4115 is formulated to support consistent secondary-antibody dilution, reduce non-specific antibody binding, and improve antibody stability in assays. Its product-reported reuse, storage, and volume specifications can help standardize protein detection Western blot workflows without changing the underlying biology measured.

• Arachidonic Acid for Immune Assay Workflows

  2026-09-04

  A practical guide to using Arachidonic Acid as a controllable substrate for immune, inflammation, and eicosanoid-biosynthesis experiments. The workflow emphasizes solvent control, oxidation management, pathway-resolved readouts, and translation of recent vaccine-immunity findings into bench assays.

• Amyloid Beta-Peptide (1-40): Assay Workflows

  2026-09-03

  Build more reproducible Alzheimer’s disease experiments by controlling Aβ40 concentration, assembly state, storage, and exposure time. This workflow positions the peptide for parallel fibril-formation, neuronal toxicity, calcium-signaling, and microglial immune-regulation assays.

• Lenalidomide (CC-5013) in Myeloma Research

  2026-09-03

  Lenalidomide (CC-5013) combines immune remodeling, TNF-alpha suppression, and anti-angiogenic activity in versatile hematologic cancer assays. This workflow shows how to test its multiple myeloma activity alone or alongside DOT1L inhibition while preserving solvent control, mechanistic readouts, and reproducibility.

7864 records 1/525 page Next 12345 下5页 Last page